QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fortress-biotech-and-cyprium-therapeutics-announce-fda-issues-crl-relating-to-nda-for-cutx-101-intended-to-treat-menkes-disease-in-pediatric-patients

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("C...

 hc-wainwright--co-maintains-buy-on-fortress-biotech-lowers-price-target-to-17

HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and lowers the price ta...

 correction-fortress-biotech-q2-adj-eps-046-misses-036-estimate-sales-16413m-beat-14534m-estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(...

 fortress-biotech-reveals-astrazenecas-anselamimab-trial-did-not-achieve-statistical-significance

-SEC Filing

 fortress-biotech-q1-eps-048-beats-049-estimate-sales-1314m-beat-1162m-estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0....

 partex-and-fortress-biotech-announces-a-strategic-collaboration-aimed-at-identifying-and-evaluating-biopharmaceutical-compounds-using-ai-for-potential-acquisition-or-licensing-by-fortress

Partex NV and Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company, today announc...

 roth-mkm-reiterates-buy-on-fortress-biotech-raises-price-target-to-16

Roth MKM analyst Jason Wittes reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and raises the price target from $15 to $16.

 india-based-sun-pharma-to-buy-us-cancer-firm-checkpoint-therapeutics-details

Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 b...

 fortress-biotech-doses-first-patient-in-phase-2-clinical-trial-of-triplex-vaccination-in-stem-cell-donors

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSC...

 fortress-biotech-cyprium-therapeutics-announce-fda-acceptance-priority-review-of-nda-for-cutx-101-for-treatment-of-menkes-disease

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025Cyprium is eligible to receive royaltie...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION